Found "Health Promotion": 1,030 results
Thailand HealthNet – International Research Alliance for Capacity Strengthening as a platform to build HTA and research capacity in Thailand and beyond (Fiscal year 2026)
68305067HI027L0Research capacity building,health technology assessment,policy decision making,multidisciplinary research network,international collaboration
The development of health technology assessment on the drug selection for the National List of Essential Medicines (NLEM) (Fiscal year 2026)
68138067RU026L0budget impact analysis,health economic evaluation,health technology assessment,Monitoring and evaluation of high cost medicines,National List of Essential Medicines
Development and evaluation of universal coverage benefit package to support access to health care for Thailand (Fiscal year 2026)
68137067RU024L0health economic evaluation,health technology assessment
PMAC 2026: HITAP highlighted innovations and launched global projects and journals, reflecting the power of evidence at both community and international levels.
In the Prince Mahidol Award Conference 2026 (PMAC 2026), held from January 26–31, 2026, at the Centara Grand & Bangkok Convention Centre at CentralWorld, the Health Intervention and Technology Assessment Program Foundation (HITAP) participated in supporting and driving the international exchange
Good Governance for Universal Health Coverage
Achieving universal health coverage (UHC) requires policy initiatives supported by long-term system reform and an accountable governance structure that can sustainably deliver all three dimensions of UHC, population coverage, breadth of benefits package, and degree of financial coverag
Your Friendly, Neighborhood GEAR Guide!
In 2015, a HITAP International Unit (HIU) survey identified the major challenges (both contextual and technical) to the conduct of rigorous economic evaluations for policymakers’ use in healthcare decision making.
• From this study, HITAP created an online platform called the Guide to health Econ
Using Health Technology Assessment to address inefficient and unequal use of Nilotinib across Indonesia
It is vital to have evidence-informed clinical practice guidelines or clinical indications to guide the usage of high-cost drugs in the benefits package under the Indonesian universal health coverage (JKN), managed by BPJS Kesehatan.
A transparent and legit mechanism is required to support and mo
Should high-cost bevacizumab be used for metastatic-colorectal cancer (mCRC) treatment in JKN in Indonesia?
Colorectal cancer is the third most common cancer in Indonesia with approximately 28,000 patients diagnosed each year. Without population-based screening, patients are often treated when they reach the advanced stage.
Bevacizumab, a newly available high-cost treatment for metastatic colorectal ca
10 / Page